Quick Answer
Fulgent Genetics, Inc. reported Total Revenue of $322.67 million for fiscal year 2025.
Fulgent Genetics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $322.67M +13.8% |
$283.47M -2.0% |
$289.21M -53.3% |
$618.97M -37.6% |
$992.58M +135.4% |
$421.71M +1196.5% |
| Revenue (ASC 606) | $322.67M +13.8% |
$283.47M -2.0% |
$289.21M -53.3% |
$618.97M -37.6% |
$992.58M +135.4% |
$421.71M +1196.5% |
| Net Income | -$60.51M -41.7% |
-$42.71M +74.6% |
-$167.82M -217.0% |
$143.40M -71.7% |
$507.36M +136.7% |
$214.31M +52243.6% |
| Total Assets | $1.21B -0.5% |
$1.22B -1.2% |
$1.24B -10.9% |
$1.39B +8.4% |
$1.28B +82.6% |
$700.46M +689.2% |
| Cash and Equivalents | $50.19M -9.0% |
$55.14M -43.4% |
$97.47M +22.6% |
$79.51M -51.8% |
$164.89M +88.6% |
$87.43M +630.7% |
| Stockholders Equity | $1.11B -1.9% |
$1.13B -0.3% |
$1.14B -10.3% |
$1.27B +9.3% |
$1.16B +103.5% |
$569.39M +587.9% |
| R&D Expense | $53.91M +10.4% |
$48.82M +17.8% |
$41.44M +43.3% |
$28.91M +19.4% |
$24.22M +109.1% |
$11.58M +77.1% |
| Operating Income | -$91.10M -23.2% |
-$73.92M +62.2% |
-$195.53M -209.5% |
$178.53M -73.6% |
$675.95M +133.0% |
$290.16M +67893.9% |
| Gross Profit | $130.88M +22.1% |
$107.22M +2.6% |
$104.46M -71.5% |
$366.90M -52.8% |
$777.05M +134.1% |
$331.90M +1701.8% |
| Shares Outstanding | 31.08M +0.8% |
30.84M +4.0% |
29.65M +0.7% |
29.44M -2.4% |
30.16M +7.0% |
28.18M +31.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $84.07M | +17.2% | +2.8% |
| Revenue (ASC 606) | September 30, 2025 | $84.07M | +17.2% | +2.8% |
| Net Income | September 30, 2025 | -$6.61M | +54.9% | +65.1% |
| Total Assets | September 30, 2025 | $1.21B | -1.6% | +1.2% |
| Cash and Equivalents | September 30, 2025 | $117.64M | +102.7% | +33.9% |
| Stockholders Equity | September 30, 2025 | $1.13B | -1.1% | +0.8% |
| R&D Expense | September 30, 2025 | $13.86M | +17.6% | +2.8% |
| Operating Income | September 30, 2025 | -$15.35M | +10.1% | +22.1% |
| Gross Profit | September 30, 2025 | $35.51M | +32.7% | +3.1% |
| Shares Outstanding | September 30, 2025 | 30.85M | +1.0% | +0.8% |
- Fulgent Genetics, Inc. reported Total Revenue of $322.67 million for fiscal year 2025.
- Fulgent Genetics, Inc. showed an increase of +13.8% in Total Revenue compared to the prior fiscal year.
- Fulgent Genetics, Inc. reported Revenue (ASC 606) of $322.67 million for fiscal year 2025.
- Fulgent Genetics, Inc. showed an increase of +13.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Fulgent Genetics, Inc. reported Net Income of -$60.51 million for fiscal year 2025.
- Fulgent Genetics, Inc. showed a decrease of -41.7% in Net Income compared to the prior fiscal year.
- Fulgent Genetics, Inc. reported Total Assets of $1.21 billion for fiscal year 2025.
- Fulgent Genetics, Inc. showed a decrease of -0.5% in Total Assets compared to the prior fiscal year.
- Fulgent Genetics, Inc. reported Cash and Equivalents of $50.19 million for fiscal year 2025.
- Fulgent Genetics, Inc. showed a decrease of -9.0% in Cash and Equivalents compared to the prior fiscal year.
- Fulgent Genetics, Inc. reported Stockholders Equity of $1.11 billion for fiscal year 2025.
- Fulgent Genetics, Inc. showed a decrease of -1.9% in Stockholders Equity compared to the prior fiscal year.
- Fulgent Genetics, Inc. reported R&D Expense of $53.91 million for fiscal year 2025.
- Fulgent Genetics, Inc. showed an increase of +10.4% in R&D Expense compared to the prior fiscal year.
- Fulgent Genetics, Inc. reported Operating Income of -$91.10 million for fiscal year 2025.
- Fulgent Genetics, Inc. showed a decrease of -23.2% in Operating Income compared to the prior fiscal year.
- Fulgent Genetics, Inc. reported Gross Profit of $130.88 million for fiscal year 2025.
- Fulgent Genetics, Inc. showed an increase of +22.1% in Gross Profit compared to the prior fiscal year.
- Fulgent Genetics, Inc. reported Shares Outstanding of 31.08 million shares for fiscal year 2025.
- Fulgent Genetics, Inc. showed an increase of +0.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: